Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

ULC0467T_S13

— · cohortSQ1

d126fd64-01e6-5893-8cfd-8e502651a4ae

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.560
  • INTERFERON_GAMMA_RESPONSE+0.530
  • ALLOGRAFT_REJECTION+0.480
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • IL6_JAK_STAT3_SIGNALING+0.430
  • TGF_BETA_SIGNALING+0.370
  • TNFA_SIGNALING_VIA_NFKB+0.350
  • COMPLEMENT+0.310
  • APOPTOSIS+0.300
  • INFLAMMATORY_RESPONSE+0.270

Top 10 suppressed

  • E2F_TARGETS-0.510
  • G2M_CHECKPOINT-0.460
  • MYC_TARGETS_V2-0.390
  • MYC_TARGETS_V1-0.280
  • OXIDATIVE_PHOSPHORYLATION-0.220
  • FATTY_ACID_METABOLISM-0.170
  • MITOTIC_SPINDLE-0.170
  • ADIPOGENESIS-0.140
  • DNA_REPAIR-0.080
  • UV_RESPONSE_UP-0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_55JW3HFM
brain-umap@2
Ganglioglioma—0.899
2TCGA-CN-4733-01A-02R-1873-07
head-neck@1
——0.887
3ERR2278883
head-neck@1
——0.884
4BS_69V8P8A0
brain-umap@2
Neurofibroma—0.883
5SRR8518191
breast-umap@18
—D0.881
6TCGA-AO-A03U-01B-21R-A10J-07
breast-umap@18
—D0.880
7TCGA-55-8299-01A-11R-2287-07
lung-landscapes@6
—cohortMD20.878
8BS_FQX1PRAJ
brain-umap@2
Neurofibroma—0.878
9TCGA-CV-6943-01A-11R-1915-07
head-neck@1
——0.877
10SRR22247245
lung-landscapes@6
—cohortMD20.876

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.560Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.530Idelalisib— uncovered
ALLOGRAFT_REJECTION0.480Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.430Inavolisib— uncovered
TGF_BETA_SIGNALING0.370Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.350Inavolisib— uncovered
COMPLEMENT0.310Inavolisib— uncovered
APOPTOSIS0.300Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.270Idelalisib— uncovered
APICAL_JUNCTION0.260Inavolisib— uncovered
HEDGEHOG_SIGNALING0.260Inavolisib— uncovered
IL2_STAT5_SIGNALING0.260Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.230Idelalisib— uncovered
UV_RESPONSE_DN0.230Inavolisib— uncovered
ANGIOGENESIS0.220Remibrutinib— uncovered
APICAL_SURFACE0.210Temsirolimus— uncovered
KRAS_SIGNALING_UP0.210Inavolisib— uncovered
COAGULATION0.190Binimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered